335 related articles for article (PubMed ID: 35537782)
1. Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
Qu YY; Sun Z; Han W; Zou Q; Xing N; Luo H; Zhang X; He C; Bian XJ; Cai J; Chen C; Wang Q; Ye DW
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35537782
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Xia L; Peng J; Lou G; Pan M; Zhou Q; Hu W; Shi H; Wang L; Gao Y; Zhu J; Zhang Y; Sun R; Zhou X; Wang Q; Wu X
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017154
[TBL] [Abstract][Full Text] [Related]
3. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Ren S; Wang X; Han BH; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38388167
[TBL] [Abstract][Full Text] [Related]
5. Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study.
Qu YY; Zhang HL; Guo H; Luo H; Zou Q; Xing N; Xia S; Sun Z; Zhang X; He C; Cai J; Zhang X; Wang Q; Ye DW
Clin Cancer Res; 2021 Nov; 27(21):5838-5846. PubMed ID: 34400414
[TBL] [Abstract][Full Text] [Related]
6. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
Ding X; Hua YJ; Zou X; Chen XZ; Zhang XM; Xu B; Ouyang YF; Tu ZW; Li HF; Duan CY; Zhang WJ; You R; Liu YP; Liu YL; Yang Q; Huang PY; Wang SN; Fan J; Chen MY
EClinicalMedicine; 2023 Jul; 61():102043. PubMed ID: 37415845
[TBL] [Abstract][Full Text] [Related]
7. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract][Full Text] [Related]
8. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
9. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
Grivas P; Pouessel D; Park CH; Barthelemy P; Bupathi M; Petrylak DP; Agarwal N; Gupta S; Fléchon A; Ramamurthy C; Davis NB; Recio-Boiles A; Sternberg CN; Bhatia A; Pichardo C; Sierecki M; Tonelli J; Zhou H; Tagawa ST; Loriot Y
J Clin Oncol; 2024 Apr; 42(12):1415-1425. PubMed ID: 38261969
[TBL] [Abstract][Full Text] [Related]
10. Camrelizumab as adjuvant therapy in urothelial carcinomas after radical surgery in people living with HIV.
Wu M; Pang Y; Zheng X; Zhao J
Int J STD AIDS; 2023 Sep; 34(10):720-727. PubMed ID: 37216934
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
14. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
Loriot Y; Petrylak DP; Rezazadeh Kalebasty A; Fléchon A; Jain RK; Gupta S; Bupathi M; Beuzeboc P; Palmbos P; Balar AV; Kyriakopoulos CE; Pouessel D; Sternberg CN; Tonelli J; Sierecki M; Zhou H; Grivas P; Barthélémy P; Tagawa ST
Ann Oncol; 2024 Apr; 35(4):392-401. PubMed ID: 38244927
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Lan C; Shen J; Wang Y; Li J; Liu Z; He M; Cao X; Ling J; Huang J; Zheng M; Zou G; Yan H; Liu Q; Yang F; Wei W; Deng Y; Xiong Y; Huang X
J Clin Oncol; 2020 Dec; 38(34):4095-4106. PubMed ID: 33052760
[TBL] [Abstract][Full Text] [Related]
16. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
18. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
19. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
[TBL] [Abstract][Full Text] [Related]
20. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]